Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pfenex Inc (PFNX)

Pfenex Inc (PFNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pfenex Inc 10790 ROSELLE STREET SAN DIEGO CA 92121 USA

www.pfenex.com P: 858-352-4400

Description:

Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 437,287
Shares Outstanding, K 34,297
Annual Sales, $ 50,330 K
Annual Net Income, $ 1,060 K
Last Quarter Sales, $ 780 K
Last Quarter Net Income, $ -10,330 K
60-Month Beta 1.32
% of Insider Shareholders 4.00%
% of Institutional Shareholders 76.72%
Float, K 32,925
% Float 96.00%

Growth:

1-Year Return 51.07%
3-Year Return 315.31%
5-Year Return -21.49%
5-Year Revenue Growth 373.03%
5-Year Earnings Growth 102.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/05/20
Earnings Per Share ttm -0.23
EPS Growth vs. Prev Qtr 3.23%
EPS Growth vs. Prev Year -25.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PFNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -11.41%
Return-on-Assets % -9.78%
Profit Margin % 2.11%
Debt/Equity 0.00
Price/Sales 8.70
Price/Cash Flow 140.87
Price/Book 5.90
Book Value/Share 2.16
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar